

IN THE CLAIMS

Please amend claims 3, 4, 7-12 and 25-27 as follows:

1. (ORIGINAL) A method for detecting gastric cancer, comprising:
 - (a) providing a biological sample; and
 - (b) detecting over-expression of a GTM family member in said sample.

2. (ORIGINAL) The method of claim 1, wherein said GTM family member is selected from the group consisting of carboxypeptidase N, polypeptide 2, 83 kDa chain (CPN2), matrix metalloproteinase 12 (MMP12), inhibin ("INHBA"), insulin-like growth factor 7 ("IGFBP7"), gamma-glutamyl hydrolase ("GGH"), leucine proline-enriched proteoglycan ("LEPRE1"), cystatin S ("CST4"), secreted frizzled-related protein 4 ("SFRP4"), asporin ("ASPN"), cell growth regulator with EF hand domain 1 ("CGREF1"), kallikrein 10 (KLK10), tissue inhibitor of metalloproteinase 1 ("TIMP1"), secreted acidic cysteine-rich protein ("SPARC"), transforming growth factor, β -induced ("TGFB1"), EGF-containing fibulin-like extracellular matrix protein 2 ("EFEMP2"), lumican ("LUM"), stannin ("SNN"), secreted phosphoprotein 1 ("SPP1"), chondroitin sulfate proteoglycan 2 ("CSPG2"), N-acylsphingosine amidohydrolase ("ASAH1"), serine protease 11 ("PRSS11"), secreted frizzled-related protein 2 ("SFRP2"), phospholipase A2, group XIIB ("PLA2G12B"), spondin 2, extracellular matrix protein ("SPON2"), olfactomedin 1 ("OLFM1"), thrombospondin repeat containing 1 ("TSRC1"), thrombospondin 2 ("THBS2"), adican, cystatin SA ("CST2"), cystatin SN ("CST1"), lysyl oxidase-like enzyme 2 ("LOXL2"), thyroglobulin ("TG"), transforming growth factor beta1 ("TGFB1"), serine or cysteine proteinase inhibitor clade H ("SERPINH1"), serine or cysteine proteinase inhibitor clade B ("SERPINB5"), matrix metalloproteinase 2 ("MMP2"), proprotein convertase subtilisin/kexin type 5 ("PCSK5") and hyaluronan glycoprotein link protein 4 ("HAPLN4").

3. (CURRENTLY AMENDED) The method of ~~claims 1-2~~ 2, wherein said step of detecting is carried out by detecting over-expression of GTM mRNA.

4. (CURRENTLY AMENDED) The method of ~~claims 1-2~~ 2, wherein said step of detecting is carried out by detecting over-expression of GMT cDNA.

5. (ORIGINAL) The method of claim 4, wherein said step of detecting is carried out using an oligonucleotide complementary to at least a portion of said GMT cDNA.
6. (ORIGINAL) The method of claim 4, wherein said step of detecting is carried out using qPCR method using a forward primer and a reverse primer.
7. (CURRENTLY AMENDED) The method of ~~claims 1 or 2~~, wherein said step of detecting is carried out by detecting over expression of a GTM protein.
8. (CURRENTLY AMENDED) The method of ~~claims 1 or 2~~, wherein said step of detecting is carried out by detecting over expression of a GTM peptide.
9. (CURRENTLY AMENDED) The method of ~~claims 7 or 8~~, wherein said step of detecting is carried out using an antibody directed against said GMT.
10. (CURRENTLY AMENDED) The method of ~~any of claims 7-9~~ claim 9, wherein said step of detecting is carried out using a sandwich-type immunoassay method.
11. (CURRENTLY AMENDED) The method of ~~any of claims 7-10~~ claim 9, wherein said antibody is a monoclonal antibody.
12. (CURRENTLY AMENDED) The method of ~~any of claims 7-10~~ claim 9, wherein said antibody is a polyclonal antiserum.
13. (ORIGINAL) A device for detecting a GTM, comprising:
 - a substrate having a GTM capture reagent thereon; and
 - a detector associated with said substrate, said detector capable of detecting a GTM associated with said capture reagent.
14. (ORIGINAL) The device of claim 13, wherein said GTM capture reagent is an oligonucleotide.

15. (ORIGINAL) The device of claim 13, wherein said GTM capture reagent is an antibody specific for either a GTM oligonucleotide, a GTM protein or a GTM peptide.
16. (ORIGINAL) A kit for detecting cancer, comprising:
a substrate having a GTM capture reagent thereon;
a means for visualizing a complex of said GMT capture agent and a GMT;
reagents; and
instructions for use.
17. (ORIGINAL) The kit of claim 16, wherein said GTM capture reagent is a GTM-specific oligonucleotide.
18. (ORIGINAL) The kit of claim 16, wherein said GTM capture reagent is a GTM-specific antibody selective for a GTM oligonucleotide, a GTM protein or a GTM peptide.
19. (ORIGINAL) A method for detecting gastric cancer, comprising the steps of:
providing a test sample from a patient suspected of having gastric cancer;
measuring the presence of a GTM protein in said test sample; and
comparing the amount of GTM present in said test sample with a value obtained from a control sample from a subject not having gastric cancer.
20. (ORIGINAL) A method for screening for gastric cancer, comprising the steps of:
providing a test sample from a test subject;
measuring the presence of a GTM in said test sample; and
comparing the amount of GTM present in said test sample with a value obtained from a control sample from a subject not having gastric cancer.
21. (ORIGINAL) The method of claim 19, wherein said GTM is a GTM protein or peptide.
22. (ORIGINAL) The method of claim 19, wherein said GTM is an oligonucleotide specific for a GTM.

23. (ORIGINAL) The method of claim 22, wherein said oligonucleotide is DNA.
24. (ORIGINAL) The method of claim 22, wherein said oligonucleotide is RNA.
25. (CURRENTLY AMENDED) The method of claim 19 ~~any of claims 18—24~~, wherein said step of measuring uses an ELISA assay.
26. (CURRENTLY AMENDED) The method of claim 19 ~~any of claims 19–21~~, wherein said test sample is obtained from plasma.
27. (CURRENTLY AMENDED) The method of claim 19 ~~any of claims 19–21~~, wherein said test sample is obtained from tissue, urine, gastric fluid, serum and stool.